American Journal of Cardiovascular Drugs

, Volume 4, Issue 3, pp 139–149

Hypercoagulability in Renal Transplant Recipients

Identifying Patients at Risk of Renal Allograft Thrombosis and Evaluating Strategies for Prevention
Leading Article

Abstract

Renal transplantation improves survival and quality of life for patients with end-stage renal disease (ESRD). Improvements in immunosuppressive therapy have reduced early allograft loss due to acute rejection to very low levels. Early allograft loss, due to acute thrombotic complications, remains a constant and proportionally increasing complication of renal transplantation. Identifying risk factor(s) for thrombosis amenable to preventive strategies has been elusive. Epidemiological studies have attempted to define risk in terms of modifiable (drugs, dialysis modality, surgical procedure) and non-modifiable (age, diabetes mellitus, vascular anomalies) factors, or identify changes in coagulation or fibrinolysis promoting a more thrombotic state. Most recently the evolution of thrombophilia research has established the potential for inherited hypercoagulability to predispose to acute allograft thrombosis. Inheritance of the factor V Leiden (FVL), prothrombin G20210A mutation, or the presence of antiphospholipid antibodies (APA) may increase the risk of renal allograft thrombosis approximately 3-fold in selected patients. Patients with ESRD due to systemic lupus erythematosus (SLE) appear at particularly high risk of thrombosis, especially if they have either APA or detectable β2-glycoprotein-1. Data for other hypercoagulable states such as hyperhomocystinemia or the C677T polymorphism of the methylenetetrahydrofolate reductase gene are deficient. Patients with APA, FVL, or prothrombin G20210A mutation also appear to have greater graft loss due to vascular rejection, possibly reflecting immunological injury upon the vascular wall exacerbated or induced by the prothrombotic state. While substantial in vitro data suggest cyclosporine is prothrombotic, an independent clinical association with allograft thrombosis is unproven. Interventions to reduce thrombotic risk including heparin, warfarin, and aspirin have been evaluated in both selected high-risk groups (heparin and warfarin) and unselected populations (heparin and aspirin). In unselected patients at low clinical risk, aspirin (75–150 mg/day) with or without a short period of unfractionated heparin (5000U twice a day for 5 days) appears to reduce the risk of renal allograft thrombosis significantly with a low risk of bleeding, especially when compared with low molecular weight heparins which risk accumulation in renal failure. In high-risk groups (identified thrombophilic risk factor, previous thrombosis, or SLE) longer period of heparin, with or without aspirin and maintenance with warfarin, should be considered. Re-transplantation following graft loss due to vascular thrombosis can be undertaken with a low risk of recurrence. Further prospective studies evaluating both putative risk factors and intervention strategies are required to determine whether routine clinical screening for thrombophilic factors is justified.

References

  1. 1.
    Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331(6): 365–76PubMedGoogle Scholar
  2. 2.
    Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725–30PubMedGoogle Scholar
  3. 3.
    ANZDATA Report 1994. Australia and New Zealand Dialysis and Transplant Registry. Editor: Disney APS, Adelaide (SA) AustraliaGoogle Scholar
  4. 4.
    Parrott NR. Early graft loss: the Cinderella of transplantation. Nephrol Dial Transplant 1995; 10 Suppl. 1:32–5PubMedGoogle Scholar
  5. 5.
    Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307–13PubMedGoogle Scholar
  6. 6.
    Matas AJ, Humar A, Gillingham KJ, et al. Five preventable causes of kidney graft loss in the 1990s: a single centre analysis. Kidney Int 2002; 62: 704–14PubMedGoogle Scholar
  7. 7.
    Kasiske BL. Ischemic heart disease after renal transplantation. Kidney Int 2002; 61: 356–69PubMedGoogle Scholar
  8. 8.
    Gray DWR. Vascular and lymphatic complications after renal transplantation. In: Morris PJ, editor. Kidney transplantation. 4th ed. Philadelphia: WB Saunders Company, 1994:314–29Google Scholar
  9. 9.
    Bakir N, Sluiter WJ, Ploeg RJ, et al. Primary renal graft thrombosis. Nephrol Dial Transplant 1996; 11: 140–7PubMedGoogle Scholar
  10. 10.
    Ojo AO, Hanson JA, Wolfe RA, et al. Dialysis modality and the risk of allograft thrombosis in adult renal transplant recipients. Kidney Int 1999; 55: 1952–60PubMedGoogle Scholar
  11. 11.
    Penny MJ, Nankivell BJ, Disney APS, et al. Renal graft thrombosis. Transplantation 1994; 58(5): 565–9PubMedGoogle Scholar
  12. 12.
    Richardson AJ, Higgins RM, Jaskowski AJ, et al. Spontaneous rupture of renal allografts: the importance of renal vein thrombosis in the cyclosporine era. Br J Surg 1990; 77(5): 558–60PubMedGoogle Scholar
  13. 13.
    Bertina RM, Rosendaal FR. Venous thrombosis-the interaction of genes and environment. N Engl J Med 1998; 338(25): 1840–1PubMedGoogle Scholar
  14. 14.
    Humar A, Johnson EM, Gillingham KJ, et al. Venous thromboembolic complications after kidney and kidney-pancreas transplantation. Transplantation 1998; 65(2): 229–34PubMedGoogle Scholar
  15. 15.
    Abramowicz D, Pradier O, Marchant A, et al. Induction of thromboses within renal allografts by high-dose prophylactic OKT3. Lancet 1992; 339: 777–8PubMedGoogle Scholar
  16. 16.
    Broyer M, Gagnadoux MF, Sierro A, et al. Preventive treatment of vascular thrombosis after kidney transplantation in children with low molecular weight heparin. Transplant Proc 1991; 23(1): 1384–5PubMedGoogle Scholar
  17. 17.
    Murphy BG, Hill CM, Middleton D, et al. Increased renal allograft thrombosis in CAPD patients. Nephrol Dial Transplant 1994; 9: 1166–9PubMedGoogle Scholar
  18. 18.
    Van der Vliet JA, Barendregt WB, Hoitsma AJ, et al. Increased incidence of renal allograft thrombosis after continuous ambulatory peritoneal dialysis. Clin Transplant 1996; 10: 51–4PubMedGoogle Scholar
  19. 19.
    Nachman RL. Thrombosis and atherogenesis: molecular connections. Blood 1992; 79(8): 1897–906PubMedGoogle Scholar
  20. 20.
    Key NS. Scratching the surface: endothelium as a regulator of thrombosis, fibrinolysis and inflammation. J Lab Clin Med 1992; 120(2): 184–6PubMedGoogle Scholar
  21. 21.
    Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997; 77(3): 408–23PubMedGoogle Scholar
  22. 22.
    Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381–9PubMedGoogle Scholar
  23. 23.
    Flier JS, Underhill LH. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326(12): 800–6Google Scholar
  24. 24.
    Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344(16): 1222–31PubMedGoogle Scholar
  25. 25.
    Rosenberg RD, Bauer KA. Prothrombin activation fragment Assay. Clin Chem 1993; 39(4): 559–60PubMedGoogle Scholar
  26. 26.
    Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70(2): 343–50PubMedGoogle Scholar
  27. 27.
    Mari B, Imbert V, Belhacene N, et al. Thrombin and thrombin resceptor agonist peptide induce early events of T-cell activation and synergize with TCR cross-linking for CD69 expression and Interleukin 2 production. J Biol Chem 1994; 269: 8517–23PubMedGoogle Scholar
  28. 28.
    Maruyama I, Shigeta K, Miyahara H, et al. Thrombin activates NK-kappa B through thrombin receptor and results in proliferation of vascular smooth muscle: role of thrombin in atherosclerosis and restenosis. Ann N Y Acad Sci 1997; 811: 429–36PubMedGoogle Scholar
  29. 29.
    Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77(1): 1–43PubMedGoogle Scholar
  30. 30.
    Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med 1993; 119: 819–27PubMedGoogle Scholar
  31. 31.
    Booth NA, Bennett B. Fibrinolysis and thrombosis. Baillieres Clin Haematol 1994; 7(3): 559–71PubMedGoogle Scholar
  32. 32.
    Schafer AI. Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994; 344: 1739–42PubMedGoogle Scholar
  33. 33.
    Federman DG, Kirsner RS. An update on hypercoagulable disorders. Arch Intern Med 2001; 161: 1051–6PubMedGoogle Scholar
  34. 34.
    Laffan MA, Tuddenham EGD. Inherited thrombophilias. Q J Med 1997; 90: 375–8Google Scholar
  35. 35.
    Braddock M, Schwachtgen JL, Houston P, et al. Fluid shear stress modulation of gene expression in endothelial cells. J Biomech 1995; 28: 1515–28Google Scholar
  36. 36.
    Humphries SE, Panahloo A, Montgomery HE, et al. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb Haemost 1997; 78(1): 457–61PubMedGoogle Scholar
  37. 37.
    Kottke-Marchant K. Genetic polymorphisms associated with venous and arterial thrombosis. Arch Pathol Lab Med 2002; 126: 295–304PubMedGoogle Scholar
  38. 38.
    Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340: 1555–64PubMedGoogle Scholar
  39. 39.
    Irish AB. The factor V Leiden mutation and risk of renal vein thrombosis in patients with nephrotic syndrome. Nephrol Dial Transplant 1997; 12(9): 1680–3PubMedGoogle Scholar
  40. 40.
    den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759–62Google Scholar
  41. 41.
    Lockshin MD. Antiphospholipid Antibody. JAMA 1997; 227(19): 1549–51Google Scholar
  42. 42.
    Koester BH, Koveker GB, Potsch B, et al. Hereditary thrombophilia as a cause of recurrent transplant thromboses. Chirurg 1994; 64(10): 809–12Google Scholar
  43. 43.
    Morrissey PE, Ramirez PJ, Gohh RY, et al. Management of thrombophilia in renal transplant recipients. Am J Transplant 2002; 2(9): 872–6PubMedGoogle Scholar
  44. 44.
    Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004–8PubMedGoogle Scholar
  45. 45.
    Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–7PubMedGoogle Scholar
  46. 46.
    Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133–4PubMedGoogle Scholar
  47. 47.
    Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504–8PubMedGoogle Scholar
  48. 48.
    Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92(10): 2800–2PubMedGoogle Scholar
  49. 49.
    Lindmarker P, Schulman S, Sten-Lindner M, et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999; 81: 684–9PubMedGoogle Scholar
  50. 50.
    Margaglione M, D’Andrea G, Colaizzo D, et al. Coexistence of factor V leiden and factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999; 82: 1583–7PubMedGoogle Scholar
  51. 51.
    Laffan M, Tuddenham E. Assessing thrombotic risk. BMJ 1998; 317: 520–3PubMedGoogle Scholar
  52. 52.
    Ridker PM, Hennekens CH, Lindpainter K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912–7PubMedGoogle Scholar
  53. 53.
    Fodinger M, Mannhalter C, Pabinger I, et al. Resistance to activated protein C (APC): mutation at ARG506 of coagulation factor V and vascular access thrombosis in hemodialysis patients. Nephrol Dial Transplant 1996; 11: 668–72PubMedGoogle Scholar
  54. 54.
    Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variationinthe3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698–703PubMedGoogle Scholar
  55. 55.
    Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G20210A gene variant. Ann Intern Med 1998; 129: 89–93PubMedGoogle Scholar
  56. 56.
    Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999–1004PubMedGoogle Scholar
  57. 57.
    Kyrie PA, Mannhalter C, Beguin S, et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287–91Google Scholar
  58. 58.
    Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338(25): 1793–7PubMedGoogle Scholar
  59. 59.
    Juhan-Vague I, Roul C, Alessi M. Increased plasma plasminogen activator inhibitor-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457–62PubMedGoogle Scholar
  60. 60.
    Riley RS, Friedline J, Rogers JS. Antiphopholipid antibodies: standardization and testing. Clin Lab Med 1997; 17(3): 395–430PubMedGoogle Scholar
  61. 61.
    Wahl DG, De Maistre E, Guillemin F, et al. Antibodies against phospholipids and β2-glycoprotein 1 increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus. Q J Med 1998; 91: 125–30Google Scholar
  62. 62.
    Pierangeli SS, Espinola RG, Liu WX, et al. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88: 245–50PubMedGoogle Scholar
  63. 63.
    Irish AB. Fibrinogen, dyslipidaemia and the acute phase response: associations with blood pressure and cardiovascular disease in patients with chronic renal disease. Atherosclerosis 1998; 137: 133–9PubMedGoogle Scholar
  64. 64.
    Irish AB. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis. Metabolism 1997; 46(1): 36–40PubMedGoogle Scholar
  65. 65.
    Irish AB, Green FR. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation and factor VII genotype. Nephrol Dial Transplant 1998; 13: 679–84PubMedGoogle Scholar
  66. 66.
    Tomura S, Nakamura Y, Doi M, et al. Fibrinogen, coagulation factor VU, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipids as cardiovascular risk factors in chronic haemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1996; 27(6): 848–54PubMedGoogle Scholar
  67. 67.
    Vaziri ND, Gonzales EC, Wang J, et al. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 1994; 23(6): 828–35PubMedGoogle Scholar
  68. 68.
    Walkowiak B, Pawlowska Z, Michalak E, et al. Expression of fibrinogen receptors on platelets of uremic patients is correlated with the content of GPIIb and plasma level of creatinine. Thromb Haemost 1994; 71(2): 164–8PubMedGoogle Scholar
  69. 69.
    Diaz-Ricart M, Estebanell E, Cases A, et al. Abnormal platelet cytoskeleton assembly in hemodialyzed patients results in deficient tyrosine phosphorylation signaling. Kidney Int 2000; 57(5): 1905–14PubMedGoogle Scholar
  70. 70.
    Baker LRI, Tucker B, Kovacs IB. Enhanced in vitro hemostasis and reduced thrombolysis in cyclosporinee-treated renal transplant recipients. Transplantation 1990; 49(5): 905–9PubMedGoogle Scholar
  71. 71.
    Garcia-Maldonaldo M, Kaufman CE, Comp PC. Decrease in endothelial cell-dependent Protein C activation induced by thrombomodulin by treatment with cyclosporinee. Transplantation 1991; 51(3): 701–5Google Scholar
  72. 72.
    Brunkwall J, Bergqvist D, Almer L-O, et al. Tissue plasminogen activator, its fast acting plasma inhibitor and Protein C after renal transplantation. Thromb Res 1995; 77(1): 105–11PubMedGoogle Scholar
  73. 73.
    Koppensteiner R, Derfler K, Ehringer H. Blood rheology after renal transplantation. Nephron 1996; 74: 328–32PubMedGoogle Scholar
  74. 74.
    Irish AB, Green FR. Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1997; 12: 167–73PubMedGoogle Scholar
  75. 75.
    Allen RD, Michie CA, Murie JA, et al. Deep venous thrombosis after renal transplantation. Surg Gynecol Obstet 1987; 164: 137–42PubMedGoogle Scholar
  76. 76.
    Wang Y, Turner N, An SF, et al. Gene expression of plasmimogen activator inhibitor 1 in transplant kidneys complicated by renal vein thrombosis: a combined study by in-situ hybridization and immunohistochemistry. Nephrol Dial Transplant 1994; 9: 296–303PubMedGoogle Scholar
  77. 77.
    Vanrenterghem Y, Roels L, Lerut T, et al. Thromboembolic complications and haemostatic changes in cyclosporine-treated cadaveric kidney allograft recipients. Lancet 1985; I: 999–1002Google Scholar
  78. 78.
    Carlsen E, Prydz H. Enhancement of procoagulant activity in stimulated mononuclear blood cells and monocytes by cyclosporinee. Transplantation 1987; 43(4): 543–8Google Scholar
  79. 79.
    Fishman SJ, Wylonis LJ, Glickman JD, et al. cyclosporine A augments human platelet sensitivity to aggregating agents by increasing fibrinogen receptor availability. J Surg Res 1991; 51: 93–8PubMedGoogle Scholar
  80. 80.
    Bombeli T, Müller M, Werner Straub P, et al. cyclosporinee-induced detachment of vascular endothelial cells initiates the extrinsic coagulation system in plasma and whole blood. J Lab Clin Med 1996; 127: 621–34PubMedGoogle Scholar
  81. 81.
    Rigotti P, Flechner SM, Van Buren CT, et al. Increased incidence of renal allograft thrombosis under cyclosporinee immunosuppression. Int Surg 1986; 71(1): 38–41PubMedGoogle Scholar
  82. 82.
    Jones RM, Murie JA, Ting A, et al. Renal vascular thrombosis of cadaveric renal allografts in patients receiving cyclosporinee, azathioprine and prednisone triple therapy. Clin Transplant 1988; 2: 124–8Google Scholar
  83. 83.
    Gruber SA, Chavers B, Payne WD, et al. Allograft renal vascular thrombosis-lack of increase with cyclosporinee immunosuppression. Transplantation 1989; 47(3): 475–8PubMedGoogle Scholar
  84. 84.
    Hohage H, Arlt M, Bruckner D, et al. Effects of cyclosporine A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients. Clin Transplant 1997; 11: 225–30PubMedGoogle Scholar
  85. 85.
    Irish AB, Green FR, Gray DW, et al. The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients. Transplantation 1997; 64(4): 604–7PubMedGoogle Scholar
  86. 86.
    Fischereder M, Gohring P, Schneeberger HS, et al. Early loss of renal transplants in patients with thrombophilia. Transplantation 1998; 65(7): 936–9PubMedGoogle Scholar
  87. 87.
    Heidenreich S, Dercken C, August C, et al. High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. J Am Soc Nephrol 1998; 9: 1309–13PubMedGoogle Scholar
  88. 88.
    Ekberg H, Svensson PJ, Simanaitis M, et al. Factor V R506Q mutation (Activated Protein C Resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection. Transplantation 2000; 69(8): 1577–81PubMedGoogle Scholar
  89. 89.
    Oh J, Schaefer F, Veldman A, et al. Heterozygous prothrombin gene mutation: a new risk factor for early renal allograft thrombosis. Transplantation 1999; 68(4): 575–8PubMedGoogle Scholar
  90. 90.
    Fischereder M, Schneeberger H, Lohse P, et al. Increased rate of renal transplant failure in patients with the G20210A mutation of the prothrombin gene. Am J Kidney Dis 2001; 38(5): 1061–4PubMedGoogle Scholar
  91. 91.
    Heidenreich S, Junker R, Wolters H, et al. Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study. J Am Soc Nephrol 2003; 14: 234–9PubMedGoogle Scholar
  92. 92.
    Pherwani AD, Winter PC, McNamee PT, et al. Is screening for factor V leiden and prothrombin G20210A mutations in renal transplantation worthwhile? Results of a large single-centre U.K. study. Transplantation 2003; 76: 603–5PubMedGoogle Scholar
  93. 93.
    Wagenknecht DR, Becker DG, Lefor WM, et al. Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation 1999; 68(2): 241–6PubMedGoogle Scholar
  94. 94.
    Wüthrich RP, Cicvara-Muzar S, Booy C, et al. Heterozygosity for the factor V leiden (G1691 A) mutation predisposes renal transplant recipients to thrombotic complications and graft loss. Transplantation 2001; 72(3): 549–50PubMedGoogle Scholar
  95. 95.
    Robertson AJ, Nargund V, Gray DWR, et al. Low dose aspirin as prophylaxis against renal-vein threombosis in renal-transplant recipients. Nephrol Dial Transplant 2000; 15: 1865–8PubMedGoogle Scholar
  96. 96.
    Murphy GJ, Taha R, Windmill DC, et al. Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. Br J Surg 2001; 88: 261–6PubMedGoogle Scholar
  97. 97.
    Friedman GS, Meier-Kreische H-U, Kaplan B, et al. Hypercoagulable states in renal transplant candidtaes: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation 2001; 72(6): 1073–8PubMedGoogle Scholar
  98. 98.
    Green FR. Genetic predisposition to thrombosis in renal transplant recipients: the factor V Q506 (Leiden) allele. Transplantation 2000; 69: 1547–8PubMedGoogle Scholar
  99. 99.
    Murphy B. Genetic polymorphisms and transplantation. Am J Kidney Dis 2001; 38(5): 1115–8PubMedGoogle Scholar
  100. 100.
    Knight RJ, Schanzer H, Rand JH, et al. Renal allograft thrombosis associated with the antiphospholipid antibody syndrome. Transplantation 1995; 60(6): 614–5PubMedGoogle Scholar
  101. 101.
    Ducloux D, Pellet E, Fournier V, et al. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation 1999; 67(1): 90–3PubMedGoogle Scholar
  102. 102.
    Manns BM, Burgess ED, Parsons HG, et al. Hyperhomocysteinaemia, anticardiolipin antibody status, and risk of vascular access thrombosis in hemodialysis patients. Kidney Int 1999; 55(1): 315–20PubMedGoogle Scholar
  103. 103.
    Sitter T, Schiffl H. Anticardiolipid antibodies in patients on regular haemodialysis: an epiphenomenon? Nephron 1993; 64(4): 655–6PubMedGoogle Scholar
  104. 104.
    Vaidya S, Sellers R, Kimball P, et al. Frequency, potential risk and therapeutic interventions in end-stage renal disease patients with antiphospholipid antibody syndrome. Transplantation 2000; 69(7): 1348–52PubMedGoogle Scholar
  105. 105.
    Radharkrishnan J, Williams GS, Appel GB, et al. Renal transplantation in anticardiolipin antibody positive lupus erythematosus patients. Am J Kidney Dis 1994; 23: 286–9Google Scholar
  106. 106.
    Stone JH, Amend WJ, Criswell LA. Antiphopholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis 1999; 34: 1040–7PubMedGoogle Scholar
  107. 107.
    Clagett GP, Anderson FA, Geerts W, et al. Prevention of venous thromboembolism. Chest 1998; 114: 531S–60SPubMedGoogle Scholar
  108. 108.
    Ubhi CS, Lam FT, Mavor AID, et al. Subcutaneous heparin therapy for cyclosporinee-immunosuppressed renal allograft recipients. Transplantation 1989; 48(5): 886–7PubMedGoogle Scholar
  109. 109.
    Alkhunaizi AM, Olyaei AJ, Barry JM, et al. Efficacy and safety of low molecular weight heparin in renal transplantation. Transplantation 1998; 66(4): 533–4PubMedGoogle Scholar
  110. 110.
    Evans SM, Giddings JC, Muraki T, et al. Expression of von Willebrand factor, Pselectin (CD62P) and thrombomodulin in human endothelial cells in culture modulated by cyclosporine A. Clin Lab Haematol 1997; 19: 115–22PubMedGoogle Scholar
  111. 111.
    PEP Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295–302Google Scholar
  112. 112.
    Shullo MA, Rose ML, Vivas C, et al. Hemorrhagic complications of enoxaparin and aspirin in patients with kidney transplants. Pharmacotherapy 2002; 22(2): 184–7PubMedGoogle Scholar
  113. 113.
    Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000; 20: 771–5PubMedGoogle Scholar
  114. 114.
    Humar A, Key N, Ramcharan T, et al. Kidney retransplants after initial graft loss to vascular thrombosis. Clin Transplant 2001; 15: 6–10PubMedGoogle Scholar
  115. 115.
    Fenton JW. Thrombin and antithrombotics. Semin Thromb Hemost 1998; 24(2): 87–91PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Department of NephrologyRoyal Perth HospitalPerthWestern Australia

Personalised recommendations